AI summary · may contain errors
Intermittent dasatinib with a weekend holiday is noninferior to continuous 100 mg daily for major molecular remission at 24 months in first-line chronic phase chronic myeloid leukemia, with 81% vs 78%.
Moving in Leukemia, Journal of Clinical Oncology, The Lancet Haematology, Blood Cancer Discovery, Nature Communications, Nature Reviews Clinical Oncology, bioRxiv and Blood.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Intermittent dasatinib with a weekend holiday is noninferior to continuous 100 mg daily for major molecular remission at 24 months in first-line chronic phase chronic myeloid leukemia, with 81% vs 78%.
AI summary · may contain errors
In 202 chronic myeloid leukemia patients treated with olverembatinib or ponatinib, the high-burden ASXL1 p.G646Wfs*12 variant is the most consistent genomic marker of inferior responses and outcomes.
AI summary · may contain errors
Overall survival in Waldenström macroglobulinemia did not change across diagnosis eras overall (p=0.64), but improved for patients aged <65 years post-2006 (median 18.8 vs 14.1 years, p=0.018).
AI summary · may contain errors
Ibrutinib is linked to hypertension in 225 chronic lymphocytic leukemia (CLL) patients, and in mice it increases arterial constriction via C/EBP-β–driven CaV1.2 upregulation.
AI summary · may contain errors
Safimaltib (JNJ-67856633) is a selective, allosteric MALT1 inhibitor that suppresses DLBCL and MCL cell growth at sub-micromolar doses and shows efficacy in mouse models.
AI summary · may contain errors
Relcobatinib (ELVN-001) shows marked selectivity for BCR::ABL1 and robust anti-tumor activity in a human CML mouse xenograft model as monotherapy and with asciminib.
AI summary · may contain errors
GAK is a tumor-selective dependency in diffuse large B-cell lymphoma, and its kinase activity is required for mitotic progression, with inhibition causing G2/M arrest and cell death.
AI summary · may contain errors
In 14 patients with Sézary syndrome on mogamulizumab, CD39/CD73/CD38 ectonucleotidase profiles on CD4+ T cells track hematologic disease activity, declining with response and returning at relapse.
AI summary · may contain errors
mTORC1 inhibition upregulates CD20 and enhances anti-CD20 monoclonal antibody efficacy in B-cell precursor acute lymphoblastic leukemia, including models with IKZF1 deletions.
AI summary · may contain errors
In transplant-ineligible newly diagnosed multiple myeloma, daratumumab plus lenalidomide/dexamethasone improved median overall survival to 90.3 months versus 64.1 months with Rd (HR 0.67).
AI summary · may contain errors
Safimaltib, a selective allosteric MALT1 protease inhibitor, shows potent antitumor activity in preclinical and clinical studies of B-cell non-Hodgkin lymphomas.
AI summary · may contain errors
AOH1996, a caPCNA inhibitor, suppresses multiple myeloma cell growth in a dose-dependent manner and induces G2-phase arrest and apoptosis.
AI summary · may contain errors
LIN28B is essential for normal human fetal liver CD34+ cells to sustain proliferation and stem-like traits, and it is required for KMT2A::AFF1 iALL transformation.
AI summary · may contain errors
The 2-butynamide warhead in Tirabrutinib and Acalabrutinib drives BTK conformational heterogeneity, unlike the acrylamide warheads in Ibrutinib and Zanubrutinib, linked to weaker PLC{gamma} signaling inhibition.
AI summary · may contain errors
Daratumumab monotherapy in high-risk smoldering multiple myeloma is linked to a significant progression-free survival benefit versus observation, with HR 0.49 (95% CI, 0.36 to 0.67; P < .001).
AI summary · may contain errors
Roginolisib potently and selectively inhibits PI3Kδ by uniquely stabilizing the catalytic C-terminal helix kα12, locking the enzyme in an inactive conformation.
AI summary · may contain errors
PSIRC3, a covalent PROTAC for Bruton’s tyrosine kinase (BTK), degrades BTK with DC50 = 0.75 nM and Dmax = 85%, unlike its non-covalent counterpart.
Journals this month
Topics moving, week to 17 Nov 2026
By field